EX-99.1 2 d13243dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

 

Name of entity  

Prima BioMed Ltd (Company)

 

 

ABN

90 009 237 889

 

 

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

1   

+Class of +securities issued or to be issued

 

  

Ordinary Shares

 

     
2   

Number of +securities issued or to be issued (if known) or maximum number which may be issued

 

  

200,000,000 Ordinary Shares were issued under the Share Purchase Plan (SPP).

 

 

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


3   Principal terms of the +securities (e.g., if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)      Pari passu with existing Ordinary Shares (PRR)
         
4   Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?      Yes (PRR)
 
  If the additional securities do not rank equally, please state:       
 
     the date from which they do       
 
     the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment       
 
     the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment       
         
5   Issue price or consideration     

5 cents per share

 

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


6   

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

    

As set out in the offer booklet for the SPP lodged with the ASX on 10 July 2015, the gross proceeds of the SPP will be used to commence two new clinical trials of IMP321 as outlined below and for general working capital purposes:

 

•    A Phase IIb chemo-immunotherapy trial of IMP321 in combination with paclitaxel to treat metastatic breast cancer in patients not eligible to receive trastuzumab (Herceptin®)

 

•    A Phase 1 trial of IMP 321 in combination with an immune checkpoint inhibitor

 

Funds will also be used to further progress the research and development programs for IMP 321 and LAG-3 in the Company’s Paris laboratory and for additional working capital.

 

       
6a   

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

     Yes
       
6b    The date the security holder resolution under rule 7.1A was passed      14 November 2014
       
6c    Number of +securities issued without security holder approval under rule 7.1      Not applicable
       
6d    Number of +securities issued with security holder approval under rule 7.1A      Not applicable
       
6e   

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

 

     Not applicable
       
6f    Number of +securities issued under an exception in rule 7.2      200,000,000 Ordinary Shares

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


6g    If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.      Not applicable
       
6h    If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements      Not applicable
       
6i    Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements      Refer Annexure 1
       
7   

Dates of entering +securities into uncertificated holdings or despatch of certificates

 

     30 July 2015

 

     Number          +Class
8     

Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

   1,951,494,601       Ordinary fully paid shares (ASX: PRR)
   77,378,696         Options exercisable at $0.20 on or before 19 June 2017 (PRRO)

 

         Number      +Class - Options
9   Number and +class of all    Amount      Exercise Price      Expiration Date
       740,741       $ 0.3390       1 February 2016
       2,800,000       $ 0.1850       1 August 2015
       200,000       $ 0.1730       20 February 2016
       1,515,752       $ 0.0774       30 June 2018
       165,116       $ 0.0774       30 June 2018
       147,628,500       $ 0.05019       12 December 2018
          
         Number      +Class – Performance Rights
         Amount      Type      Expiration Date
       11,467,525         STI       30 October 2015
       26,715,686         LTI       30 October 2018
       6,004,902         NED PRs       Each tranche of NED PRs will expire 30 days from each tranche vesting date indicated in this appendix 3B released on 26 November 2014.

 

10    Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)      Unchanged

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Part 2 - Bonus issue or pro rata issue

 

11    Is security holder approval required?      Not applicable
       
12    Is the issue renounceable or non-renounceable?      Not applicable
       
13    Ratio in which the +securities will be offered      Not applicable
       
14    +Class of +securities to which the offer relates      Not applicable
       
15    +Record date to determine entitlements      Not applicable
       
16    Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?      Not applicable
       
17    Policy for deciding entitlements in relation to fractions      Not applicable
       
18   

Names of countries in which the entity has +security holders who will not be sent new issue documents

 

Note: Security holders must be told how their entitlements are to be dealt with.

 

Cross reference: rule 7.7.

     Not applicable
       
19    Closing date for receipt of acceptances or renunciations      Not applicable

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


20   

Names of any underwriters

 

     Not applicable
            
21    Amount of any underwriting fee or commission      Not applicable
            
22   

Names of any brokers to the issue

 

     Not applicable
            
23    Fee or commission payable to the broker to the issue      Not applicable
            
24    Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders      Not applicable
            
25    If the issue is contingent on +security holders’ approval, the date of the meeting      Not applicable
            
26    Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled      Not applicable
            
27    If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders      Not applicable
            
28    Date rights trading will begin (if applicable)      Not applicable
       
29   

Date rights trading will end (if applicable)

 

 

     Not applicable
            
30    How do +security holders sell their entitlements in full through a broker?      Not applicable
            
31    How do +security holders sell part of their entitlements through a broker and accept for the balance?      Not applicable
       
32    How do +security holders dispose of their entitlements (except by sale through a broker)?      Not applicable
            
33   

+Despatch date

 

     Not applicable

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

34    Type of securities

(tick one)

(a)    x    Securities described in Part 1
(b)    ¨   

All other securities

 

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

 

35    ¨    If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
36    ¨   

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

 

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37    ¨    A copy of any trust deed for the additional +securities

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Entities that have ticked box 34(b)

 

38   Number of securities for which +quotation is sought        Not applicable
           
39   Class of +securities for which quotation is sought        Not applicable
           
40  

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

 

If the additional securities do not rank equally, please state:

       Not applicable
 
     the date from which they do       
 
     the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment       
 
     the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment       
                 
41  

Reason for request for quotation now

 

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another security, clearly identify that other security)

       Not applicable
            
         

  Number

   +Class
42   Number and +class of all +securities quoted on ASX (including the securities in clause 38)        Not applicable     

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Quotation agreement

 

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2 We warrant the following to ASX.

 

    The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

    There is no reason why those +securities should not be granted +quotation.

 

    An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

    Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

    If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

Sign here:   LOGO     Date: 30 July 2015
  Company secretary    
Print name:   Deanne Miller    

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Appendix 3B – Annexure 1

Calculation of placement capacity under

rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

 

Rule 7.1 – Issues exceeding 15% of capital

 

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

 

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

 

      

 

  1,228,709,341

 

Add the following:

        

 

•     

 

 

Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

         599,641,810

 

 

 

Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

        

 

 

 

Number of partly paid +ordinary securities that became fully paid in that 12 month period

        

 

Note:

        
     

  Include only ordinary securities here – other classes of equity securities cannot be added         
     

  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed         
     

 

It may be useful to set out issues of securities on different dates as separate line items

 

        

 

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

 

      

 

  Nil

 

“A”

 

      

 

  1,828,351,151

 

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


 

Step 2: Calculate 15% of “A”

 

 

“B”

      

 

  0.15

 

  [Note: this value cannot be changed]

 

 

Multiply “A” by 0.15

 

    

 

  274,252,673

 

 

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

 

 

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

     228,000,000
   
•        Under an exception in rule 7.2       
   
  Under rule 7.1A       
   
  With security holder approval under rule 7.1 or rule 7.4       

 

Note:

 

      
  This applies to equity securities, unless specifically excluded – not just ordinary securities       
   
  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed       
   
 

It may be useful to set out issues of securities on different dates as separate line items

 

        

 

“C”

       228,000,000

 

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

 

 

“A” x 0.15

 

Note: number must be same as shown in Step 2

 

      

 

  274,252,673

 

Subtract “C”

 

Note: number must be same as shown in Step 3

 

      

 

  228,000,000

 

Total [“A” x 0.15] – “C”

      

  46,252,673

 

  [Note: this is the remaining placement capacity under

  rule 7.1]

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Part 2

 

Rule 7.1A – Additional placement capacity for eligible entities

 

 

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

 

 

“A”

 

Note: number must be same as shown in Step 1 of Part 1

 

      

 

  1,828,351,151

 

Step 2: Calculate 10% of “A”

 

 

“D”

      

 

  0.10

 

  Note: this value cannot be changed

 

Multiply “A” by 0.10

 

      

 

  182,835,115

 

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

 

 

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

 

Notes:

 

    

 

  95,143,450

 

•     

 

 

 

This applies to equity securities – not just ordinary securities

 

      

 

 

 

Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

 

      

 

 

 

Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

 

      

 

 

 

It may be useful to set out issues of securities on different dates as separate line items

 

        

 

“E”

 

          

 

  95,143,450

 

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889


Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

“A” x 0.10

 

Note: number must be same as shown in Step 2

   182,335,115

Subtract “E”

 

Note: number must be same as shown in Step 3

   95,143,450

Total [“A” x 0.10] – “E”

  

87,691,665

 

Note: this is the remaining placement capacity under rule 7.1A

 

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 8569 1880

www.primabiomed.com.au    ABN: 90 009 237 889